NB

Nionyx Bio at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Nionyx Bio brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV capsids that reach kidney cells. It covers capsid validation in human kidney explants and animal models and a dual-vector candidate for X-linked Alport syndrome.

OrganizationESGCT 2026 Attendance
NB
Nionyx Bio
Biotech
Develops kidney-targeted AAV gene therapies using its NYX capsids, led by ONYX-101 for X-linked Alport syndrome.
Poster
Thu Oct 29
2:00pm–4:00pm
Next-generation AAV capsids for kidney cell transduction validated in human kidney explants, renal cell systems, and translational in vivo models (NYX capsids)
AAVs / non integrative vectors
Poster
Thu Oct 29
2:00pm–4:00pm
ONYX-101: development of a kidney-targeted dual-vector AAV gene therapy candidate for X-linked Alport syndrome using NYX capsids
AAVs / non integrative vectors

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Nionyx Bio

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction